Literature DB >> 25240801

Medical specialty-related adherence to anti-osteoporotic regimens in fragility hip fracture patients.

Chung-Yuan Hsu1, Wen-Chan Chiu, Jia-Feng Chen, Ching-Lan Chou, Yu-Jih Su, Shan-Fu Yu, Tien-Tsai Cheng.   

Abstract

There is poor adherence in the management of osteoporotic fractures. We designed a study to investigate adherence to osteoporotic regimens among osteoporotic hip fracture patients and to analyze the risk factors associated with poor compliance. This retrospective chart-review study was carried out using a database of osteoporotic hip fracture patients at a medical center in Taiwan for the period 2001-2007. Adherence was assessed using compliance and persistence. Compliance was calculated by the medication possession ratio (MPR) and persistence by the time from treatment initiation to discontinuation. The MPR and corresponding risk factors for poor compliance (MPR < 80 %) were evaluated for year 1. The year 2 results were analyzed only for those subjects with good compliance (MPR ≥ 80 %) at the end of year 1. There were 366 osteoporotic hip fracture patients (323 women, 43 men) with a mean age of 73.9 ± 7.6 years. Of these, 53.8 % had good compliance for year 1 and 68.5 % for year 2. During 2 years of follow-up, the overall persistence ratio was 33.1 %. The risk factor associated with poor compliance in the first year was index prescription by orthopedists [odds ratio (OR) 1.69, 95 % confidence interval (CI) 1.10-2.59]. Subjects with hypertension (OR 0.69, 95 % CI 0.46-0.99) had good compliance. Index prescription by orthopedists (OR 2.44, 95 % CI 1.31-4.51) was the sole risk factor for poor compliance in year 2. In conclusion, although adherence to osteoporotic regimens was sub-optimal in hip fracture patients, the majority of patients' decreased adherence occurred within the first year. Medical specialties showed different adherences in both year 1 and year 2.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25240801     DOI: 10.1007/s00774-014-0621-7

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  53 in total

Review 1.  How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.

Authors:  Deborah T Gold; Ivy M Alexander; Mark P Ettinger
Journal:  Ann Pharmacother       Date:  2006-05-30       Impact factor: 3.154

2.  Medical practice and related insurance.

Authors:  Vijay Chormunge; Vasantrao Pawar; Ajay Patil
Journal:  J Indian Med Assoc       Date:  2012-03

3.  Compliance with osteoporosis medications.

Authors:  Daniel H Solomon; Jerry Avorn; Jeffrey N Katz; Joel S Finkelstein; Marilyn Arnold; Jennifer M Polinski; M Alan Brookhart
Journal:  Arch Intern Med       Date:  2005-11-14

4.  The human cost of fracture.

Authors:  Julie A Pasco; Kerrie M Sanders; Frouckje M Hoekstra; Margaret J Henry; Geoffrey C Nicholson; Mark A Kotowicz
Journal:  Osteoporos Int       Date:  2005-10-14       Impact factor: 4.507

5.  Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment.

Authors:  L Boudou; B Gerbay; F Chopin; E Ollagnier; P Collet; T Thomas
Journal:  Osteoporos Int       Date:  2011-04-29       Impact factor: 4.507

6.  Mortality after osteoporotic fractures.

Authors:  O Johnell; J A Kanis; A Odén; I Sernbo; I Redlund-Johnell; C Petterson; C De Laet; B Jönsson
Journal:  Osteoporos Int       Date:  2003-10-30       Impact factor: 4.507

7.  Secondary prevention of osteoporotic fractures--an "OPTIMAL" model of care from Singapore.

Authors:  M Chandran; M Z W Tan; M Cheen; S B Tan; M Leong; T C Lau
Journal:  Osteoporos Int       Date:  2013-04-25       Impact factor: 4.507

8.  Compliance with pharmacologic therapy for osteoporosis.

Authors:  Robert A Yood; Srinivas Emani; John I Reed; Barbara Edelman Lewis; Mary Charpentier; Eva Lydick
Journal:  Osteoporos Int       Date:  2003-09-19       Impact factor: 4.507

9.  Comparison of drug adherence rates among patients with seven different medical conditions.

Authors:  Becky A Briesacher; Susan E Andrade; Hassan Fouayzi; K Arnold Chan
Journal:  Pharmacotherapy       Date:  2008-04       Impact factor: 4.705

10.  High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database.

Authors:  W C Chie; R S Yang; J P Liu; K S Tsai
Journal:  Osteoporos Int       Date:  2004-05-20       Impact factor: 4.507

View more
  2 in total

1.  Oral bisphosphonate prescription and non-adherence at 12 months in patients with hip fractures treated in an acute geriatric unit.

Authors:  A Gamboa; E Duaso; P Marimón; M Sandiumenge; E Escalante; C Lumbreras; A Tarrida
Journal:  Osteoporos Int       Date:  2018-08-03       Impact factor: 4.507

2.  Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study.

Authors:  E M C Lau; R Dinavahi; Y C Woo; C-H Wu; J Guan; J Maddox; C Tolman; W Yang; C S Shin
Journal:  Osteoporos Int       Date:  2020-02-11       Impact factor: 4.507

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.